Assessment of regional changes in skeletal metabolism following 3 and 18 months of teriparatide treatment

• Published in: Journal of bone and mineral research Vol. 25; no. 5; pp. 960 - 967
• Main Authors: Moore, Amelia EB, Blake, Glen M, Taylor, Kathleen A, Rana, Asad E, Wong, Mayme, Chen, Peiqi, Fogelman, Ignac
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.05.2010; Wiley; Oxford University Press
• Subjects: Aged; Aged, 80 and over; Alkaline Phosphatase - metabolism; Biological and medical sciences; Bone and Bones - diagnostic imaging; Bone and Bones - metabolism; Bone Density - drug effects; bone remodeling; bone turnover markers; Collagen Type I - urine; Female; Fundamental and applied biological sciences. Psychology; Humans; Middle Aged; osteoporosis; Osteoporosis, Postmenopausal - diagnostic imaging; Osteoporosis, Postmenopausal - drug therapy; Peptide Fragments - metabolism; Peptides - urine; Procollagen - metabolism; radionuclide bone scan; Radionuclide Imaging; Radiopharmaceuticals; Skeleton and joints; Technetium Tc 99m Medronate; teriparatide; Teriparatide - therapeutic use; Vertebrates: osteoarticular system, musculoskeletal system; Diseases of the osteoarticular system; Bone remodeling; Metabolism; Osteoarticular system; Osteoporosis; Osteoforming; Vertebrata; Mammalia; Treatment; Turnover; Bone; Teriparatide; BONE TURNOVER MARKERS; RADIONUCLIDE BONE SCAN
• ISSN: 0884-0431; 1523-4681; 1523-4681
• DOI: 10.1359/jbmr.091108

Teriparatide (TPTD) increases skeletal mass, bone turnover markers, and bone strength, but in vivo effects at individual skeletal sites have not been characterized. Quantitative radionuclide imaging studies reflect bone blood flow and osteoblast activity to assess regional changes in bone metabolism...